Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.
Identifieur interne : 000535 ( Ncbi/Checkpoint ); précédent : 000534; suivant : 000536Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.
Auteurs : E. Nurmi [Finlande] ; H M Ruottinen ; J. Bergman ; M. Haaparanta ; O. Solin ; P. Sonninen ; J O RinneSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2001.
English descriptors
- KwdEn :
- Adult, Aged, Caudate Nucleus (radionuclide imaging), Dihydroxyphenylalanine (analogs & derivatives), Dihydroxyphenylalanine (diagnostic use), Disease Progression, Female, Follow-Up Studies, Humans, Male, Middle Aged, Parkinson Disease (radionuclide imaging), Putamen (radionuclide imaging), Tomography, Emission-Computed.
- MESH :
- chemical , analogs & derivatives : Dihydroxyphenylalanine.
- chemical , diagnostic use : Dihydroxyphenylalanine.
- radionuclide imaging : Caudate Nucleus, Parkinson Disease, Putamen.
- Adult, Aged, Disease Progression, Female, Follow-Up Studies, Humans, Male, Middle Aged, Tomography, Emission-Computed.
Abstract
The aim of this study was to investigate the rate of progression in Parkinson's disease (PD) with 6-[(18)F]fluoro-L-dopa (FDOPA) positron emission tomography (PET). We investigated 21 patients with PD and eight healthy controls. Ten of the patients were de novo at the time of the first PET scan and antiparkinsonian medication was started thereafter, with a favourable response. A FDOPA PET scan was carried out twice at an approximately 5-year interval. The regions of interest were drawn on individual magnetic resonance imaging (MRI) images, matched with the PET images. At the first PET scan, in PD patients the mean k(i)(occ) (x 10(-3) min(-1)) in the anterior putamen was 5.6 +/- 2.7 (mean +/- S.D.; 55% of the control mean) and in the posterior putamen 4.5 +/- 2.4 (45% of the control mean). The k(i)(occ) value for the caudate nucleus was 7.5 +/- 2.1 (x 10(-3) min(-1); 76% of the control mean). The FDOPA uptake declined by the time of the second PET scan and the annual rate of decline was 8.3 +/- 6.3% (P < 0.001) of the baseline mean in the anterior putamen and 10.3 +/- 4.8% (P < 0.001) in the posterior putamen. In the caudate nucleus, FDOPA uptake decreased by 5.9 +/- 5.1% (P < 0.001) of the baseline mean per year. The estimated preclinical period was longest for the posterior putamen being 6.5 years. For the anterior putamen the preclinical period was 4.6 years. In the caudate nucleus, the estimated FDOPA uptake was at normal level at disease onset. In healthy controls, there was no significant decline in FDOPA uptake in any striatal subregion. Our results suggest that the disease process in PD first affects posterior putamen, followed by the anterior putamen and the caudate nucleus, but once started, the absolute rate of decline is the same. In healthy controls, no significant decline in FDOPA was detected.
PubMed: 11481683
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003D16
- to stream PubMed, to step Curation: 003D16
- to stream PubMed, to step Checkpoint: 003C59
- to stream Ncbi, to step Merge: 000535
- to stream Ncbi, to step Curation: 000535
Links to Exploration step
pubmed:11481683Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.</title><author><name sortKey="Nurmi, E" sort="Nurmi, E" uniqKey="Nurmi E" first="E" last="Nurmi">E. Nurmi</name><affiliation wicri:level="4"><nlm:affiliation>Department of Neurology, and Turku PET Centre, University of Turku, Turku, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Neurology, and Turku PET Centre, University of Turku, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName><orgName type="university">Université de Turku</orgName></affiliation></author><author><name sortKey="Ruottinen, H M" sort="Ruottinen, H M" uniqKey="Ruottinen H" first="H M" last="Ruottinen">H M Ruottinen</name></author><author><name sortKey="Bergman, J" sort="Bergman, J" uniqKey="Bergman J" first="J" last="Bergman">J. Bergman</name></author><author><name sortKey="Haaparanta, M" sort="Haaparanta, M" uniqKey="Haaparanta M" first="M" last="Haaparanta">M. Haaparanta</name></author><author><name sortKey="Solin, O" sort="Solin, O" uniqKey="Solin O" first="O" last="Solin">O. Solin</name></author><author><name sortKey="Sonninen, P" sort="Sonninen, P" uniqKey="Sonninen P" first="P" last="Sonninen">P. Sonninen</name></author><author><name sortKey="Rinne, J O" sort="Rinne, J O" uniqKey="Rinne J" first="J O" last="Rinne">J O Rinne</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2001">2001</date><idno type="RBID">pubmed:11481683</idno><idno type="pmid">11481683</idno><idno type="wicri:Area/PubMed/Corpus">003D16</idno><idno type="wicri:Area/PubMed/Curation">003D16</idno><idno type="wicri:Area/PubMed/Checkpoint">003C59</idno><idno type="wicri:Area/Ncbi/Merge">000535</idno><idno type="wicri:Area/Ncbi/Curation">000535</idno><idno type="wicri:Area/Ncbi/Checkpoint">000535</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.</title><author><name sortKey="Nurmi, E" sort="Nurmi, E" uniqKey="Nurmi E" first="E" last="Nurmi">E. Nurmi</name><affiliation wicri:level="4"><nlm:affiliation>Department of Neurology, and Turku PET Centre, University of Turku, Turku, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Neurology, and Turku PET Centre, University of Turku, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName><orgName type="university">Université de Turku</orgName></affiliation></author><author><name sortKey="Ruottinen, H M" sort="Ruottinen, H M" uniqKey="Ruottinen H" first="H M" last="Ruottinen">H M Ruottinen</name></author><author><name sortKey="Bergman, J" sort="Bergman, J" uniqKey="Bergman J" first="J" last="Bergman">J. Bergman</name></author><author><name sortKey="Haaparanta, M" sort="Haaparanta, M" uniqKey="Haaparanta M" first="M" last="Haaparanta">M. Haaparanta</name></author><author><name sortKey="Solin, O" sort="Solin, O" uniqKey="Solin O" first="O" last="Solin">O. Solin</name></author><author><name sortKey="Sonninen, P" sort="Sonninen, P" uniqKey="Sonninen P" first="P" last="Sonninen">P. Sonninen</name></author><author><name sortKey="Rinne, J O" sort="Rinne, J O" uniqKey="Rinne J" first="J O" last="Rinne">J O Rinne</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2001" type="published">2001</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Caudate Nucleus (radionuclide imaging)</term><term>Dihydroxyphenylalanine (analogs & derivatives)</term><term>Dihydroxyphenylalanine (diagnostic use)</term><term>Disease Progression</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (radionuclide imaging)</term><term>Putamen (radionuclide imaging)</term><term>Tomography, Emission-Computed</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Dihydroxyphenylalanine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Dihydroxyphenylalanine</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Caudate Nucleus</term><term>Parkinson Disease</term><term>Putamen</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Disease Progression</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Tomography, Emission-Computed</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this study was to investigate the rate of progression in Parkinson's disease (PD) with 6-[(18)F]fluoro-L-dopa (FDOPA) positron emission tomography (PET). We investigated 21 patients with PD and eight healthy controls. Ten of the patients were de novo at the time of the first PET scan and antiparkinsonian medication was started thereafter, with a favourable response. A FDOPA PET scan was carried out twice at an approximately 5-year interval. The regions of interest were drawn on individual magnetic resonance imaging (MRI) images, matched with the PET images. At the first PET scan, in PD patients the mean k(i)(occ) (x 10(-3) min(-1)) in the anterior putamen was 5.6 +/- 2.7 (mean +/- S.D.; 55% of the control mean) and in the posterior putamen 4.5 +/- 2.4 (45% of the control mean). The k(i)(occ) value for the caudate nucleus was 7.5 +/- 2.1 (x 10(-3) min(-1); 76% of the control mean). The FDOPA uptake declined by the time of the second PET scan and the annual rate of decline was 8.3 +/- 6.3% (P < 0.001) of the baseline mean in the anterior putamen and 10.3 +/- 4.8% (P < 0.001) in the posterior putamen. In the caudate nucleus, FDOPA uptake decreased by 5.9 +/- 5.1% (P < 0.001) of the baseline mean per year. The estimated preclinical period was longest for the posterior putamen being 6.5 years. For the anterior putamen the preclinical period was 4.6 years. In the caudate nucleus, the estimated FDOPA uptake was at normal level at disease onset. In healthy controls, there was no significant decline in FDOPA uptake in any striatal subregion. Our results suggest that the disease process in PD first affects posterior putamen, followed by the anterior putamen and the caudate nucleus, but once started, the absolute rate of decline is the same. In healthy controls, no significant decline in FDOPA was detected.</div></front></TEI><affiliations><list><country><li>Finlande</li></country><region><li>Finlande occidentale</li></region><settlement><li>Turku</li></settlement><orgName><li>Université de Turku</li></orgName></list><tree><noCountry><name sortKey="Bergman, J" sort="Bergman, J" uniqKey="Bergman J" first="J" last="Bergman">J. Bergman</name><name sortKey="Haaparanta, M" sort="Haaparanta, M" uniqKey="Haaparanta M" first="M" last="Haaparanta">M. Haaparanta</name><name sortKey="Rinne, J O" sort="Rinne, J O" uniqKey="Rinne J" first="J O" last="Rinne">J O Rinne</name><name sortKey="Ruottinen, H M" sort="Ruottinen, H M" uniqKey="Ruottinen H" first="H M" last="Ruottinen">H M Ruottinen</name><name sortKey="Solin, O" sort="Solin, O" uniqKey="Solin O" first="O" last="Solin">O. Solin</name><name sortKey="Sonninen, P" sort="Sonninen, P" uniqKey="Sonninen P" first="P" last="Sonninen">P. Sonninen</name></noCountry><country name="Finlande"><region name="Finlande occidentale"><name sortKey="Nurmi, E" sort="Nurmi, E" uniqKey="Nurmi E" first="E" last="Nurmi">E. Nurmi</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000535 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 000535 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:11481683
|texte= Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:11481683" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |